[LCID Study Number: 20223039]

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match SubStudy)

The purpose of this study is to investigate how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab works in treating patients with non-small cell lung cancer (NSCLC) that has spread to other places in the body (advanced/metastatic).

Disease/Condition: Non-Small Cell Lung Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Addison Gilbert Hospital; Beverly Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421